Skip to Main Content

Author Details

Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
2010
52
18
PMIDPaper TitleJournal TitlePublished Year
36761420Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy.Front Oncol2023
37820398Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.Gynecol Oncol2023
37392382Integration of cancer-related genetic landscape of Eph receptors and ephrins with proteomics identifies a crosstalk between EPHB6 and EGFR.Cell Rep2023
36976175A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.Clin Cancer Res2023
36587138A CRISPR Platform for Targeted In Vivo Screens.Methods Mol Biol2023
35184384Differential expression of HNF1A and HNF1A-AS1 in colon cancer cells.IUBMB Life2022
36123435Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel.Sci Rep2022
35883689A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers.Cells2022
36077749Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma.Cancers (Basel)2022
33330905APOBEC1 cytosine deaminase activity on single-stranded DNA is suppressed by replication protein A.Nucleic Acids Res2021
33828156Mining the plasma-proteome associated genes in patients with gastro-esophageal cancers for biomarker discovery.Sci Rep2021
34590285Computational Prediction of Chemical Tools for Identification and Validation of Synthetic Lethal Interaction Networks.Methods Mol Biol2021
34590278INCISOR: An Algorithm to Identify Synthetic Rescue Mediators of Resistance to Targeted and Immunotherapy.Methods Mol Biol2021
34590274Identification of Synthetic Lethal Interactions Using High-Throughput, Arrayed CRISPR/Cas9-Based Platforms.Methods Mol Biol2021
34811362Sympathetic signaling facilitates progression of neuroendocrine prostate cancer.Cell Death Discov2021
34452919Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors.Sci Adv2021
34233649Identification of novel genes involved in apoptosis of HIV-infected macrophages using unbiased genome-wide screening.BMC Infect Dis2021
33430292Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.Cancers (Basel)2021
33066048The CINs of Polo-Like Kinase 1 in Cancer.Cancers (Basel)2020
30616753A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.Trends Cancer2019
31416843Banding Together: A Systematic Comparison of The Cancer Genome Atlas and the Mitelman Databases.Cancer Res2019
31351478Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer.BMC Med Genomics2019
30817936Targeting the CINful genome: Strategies to overcome tumor heterogeneity.Prog Biophys Mol Biol2019
30548903Cell-based high-throughput screen for small molecule inhibitors of Bax translocation.J Cell Mol Med2019
30548174Molecular characterization of an MLL1 fusion and its role in chromosomal instability.Mol Oncol2019
30651078Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.BMC Cancer2019
29700392EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.Oncogene2018
30203962Discovering Selective Binders for Photoswitchable Proteins Using Phage Display.ACS Synth Biol2018
29899842High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines.Oncotarget2018
30140170Global phosphoproteomic analysis identifies SRMS-regulated secondary signaling intermediates.Proteome Sci2018
30374409Expression-based analyses indicate a central role for hypoxia in driving tumor plasticity through microenvironment remodeling and chromosomal instability.NPJ Syst Biol Appl2018
30419054Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.PLoS One2018
28583138Molecular characterization of breast cancer cell lines through multiple omic approaches.Breast Cancer Res2017
28432350Enhancing the throughput and multiplexing capabilities of next generation sequencing for efficient implementation of pooled shRNA and CRISPR screens.Sci Rep2017
28157508Multilayered Control of Alternative Splicing Regulatory Networks by Transcription Factors.Mol Cell2017
29196508An integrated computational and experimental study uncovers FUT9 as a metabolic driver of colorectal cancer.Mol Syst Biol2017
29069723Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer.Oncotarget2017
29116180The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment.Sci Rep2017
29348886FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.Oncotarget2017
26810754Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.Breast Cancer Res2016
27557495Therapeutic relevance of the protein phosphatase 2A in cancer.Oncotarget2016
27418135Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.Oncotarget2016
25877919Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming.Genes Dev2015
26109054Corrigendum: Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming.Genes Dev2015
23974104High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors.Cell Cycle2013
24104479A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities.Mol Syst Biol2013
24265703RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.PLoS One2013
22009677PhenoM: a database of morphological phenotypes caused by mutation of essential genes in Saccharomyces cerevisiae.Nucleic Acids Res2012
22984072Global gene deletion analysis exploring yeast filamentous growth.Science2012
22585861Essential gene profiles in breast, pancreatic, and ovarian cancer cells.Cancer Discov2012
  • 1 - 50 of 52

Recommended Authors

Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Jordi Carreras Puigvert
Department of Pharmaceutical Biosciences, Uppsala University
Career Start Year 2009
Number of shared co-authors 0
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 0
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 1
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 0
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 1
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 0
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 1
Jesse S Boehm
Broad Institute of Harvard and MIT
Career Start Year 2004
Number of shared co-authors 0
Sourav Bandyopadhyay
University of California San Francisco
Career Start Year 2004
Number of shared co-authors 0
Silvano Piazza
International Centre for Genetic Engineering and Biotechnology
Career Start Year 2004
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 0
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 0
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 2
Mariano J Alvarez
Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center
Career Start Year 2000
Number of shared co-authors 0
Wenyan Zhong
Oncology R&D
Career Start Year 2000
Number of shared co-authors 0
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Mathew J Garnett
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 2
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 0
Barbara A Weir
Janssen Research and Development LLC
Career Start Year 1997
Number of shared co-authors 0
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 1
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 1
David E Root
Broad Institute of Harvard and MIT
Career Start Year 1993
Number of shared co-authors 2
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 0
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 0
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 1
Matthew Meyerson
Broad Institute
Career Start Year 1983
Number of shared co-authors 2
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 1

Collaborators

Franco J Vizeacoumar
College of Medicine, University of Saskatchewan
Co-authored papers 38
Andrew Freywald
College of Medicine, University of Saskatchewan
Co-authored papers 22
Alessandro Datti
University of Perugia
Co-authored papers 14
Jeffrey L Wrana
Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital
Co-authored papers 5
Brenda J Andrews
University of Toronto
Co-authored papers 5
Tanya Freywald
University of Saskatchewan
Co-authored papers 5
Charles Boone
University of Toronto
Co-authored papers 5
Zhaolei Zhang
University of Toronto
Co-authored papers 4
Jason Moffat
University of Toronto
Co-authored papers 3
Stephanie Danielle MacNeil
Schulich School of Medicine and Dentistry, Western University
Co-authored papers 3
Zhijian Li
University of Toronto
Co-authored papers 3
Joe S Mymryk
University of Western Ontario
Co-authored papers 3
John Yoo
Schulich School of Medicine & Dentistry, Western University
Co-authored papers 3
Nicole Pinto
School of Public Policy at the University of Calgary
Co-authored papers 3
Anthony C Nichols
University of Western Ontario
Co-authored papers 3
Benjamin J Blencowe
University of Toronto
Co-authored papers 3
Kevin Fung
Schulich School of Medicine & Dentistry, Western University, Victoria Hospital
Co-authored papers 3
Paul C Boutros
University of California los angeles
Co-authored papers 3
Qun Pan
University of Toronto
Co-authored papers 3
Kara M Ruicci
Schulich School of Medicine and Dentistry, Western University
Co-authored papers 3
John W Barrett
University of Western Ontario
Co-authored papers 3
Hong Han
Hangzhou City University
Co-authored papers 3
Sondra Bahr
University of Toronto, College Street
Co-authored papers 2
Morgan Black
Schulich School of Medicine and Dentistry, Western University
Co-authored papers 2
Michael Costanzo
Co-authored papers 2
Zeynep Coban Akdemir
Baylor College of Medicine
Co-authored papers 2
Anne-Claude Gingras
Lunenfeld-Tanenbaum Research Institute
Co-authored papers 2
Ke Jin
West China Hospital, Sichuan University
Co-authored papers 2
Kevin R Brown
College Street, University of Toronto
Co-authored papers 2
David A Palma
University of Western Ontario
Co-authored papers 2
Release 1.2